Clinical Trial Update: A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of HS130 in combination with Viagenpumatucel-L (HS110) in patients with advanced solid tumors has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• HS130 (null)
• Viagenpumatucel-L (HS110) (Viagenpumatucel-L)

Snippet

Sponsor: Heat Biologics | Conditions: Advanced Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2023-08-23